(129 days)
The RM Electrode® is a contact lens electrode intended to be applied on the cornea and to be used for the measurement and recording of electroretinography (ERG) signals, to support the diagnosis of retinal dysfunctions. It is indicated for use in patients aged 12 years and above undergoing diagnostic full-field electroretinogram (ERG) recording procedures.
The RM Electrode® is a single use, disposable device.
The RM Electrode® is a contact lens-type corneal electrode for use in electroretinography (ERG) procedures. Like other corneal electrodes classified under 21 CFR 886.1220 and cleared under product code HLZ, the RM Electrode is used for the measurement and recording of ERG signals, to support the diagnosis of retinal dysfunctions. It has four components, including (1) the contact lens (substrate), which supports the conductive element (electrode ring) and allows light from the stimulus source to enter the eye; (2) the electrode ring, which is the conductive element of the device; (3) the lead wire, which is connected to the electrode ring extension and terminates in an industry standard 1.5mm female "touchproof" connector that connects to a commercially available ERG recording system (not part of the subject device); and (4) heat shrink tubing which covers the electrode ring extension and junction with the lead wire. The device materials were demonstrated to be biocompatible.
The RM Electrode® is not a powered device. As with the predicate device (ERG Jet Electrode), it is a passive sensor for recording bioelectric signals from the surface of the eye and transmitting them to an ERG recording system. From an electrical perspective, the device is a single conductor that connects the eye surface to a data recorder.
The provided text describes the regulatory clearance of a medical device, the RM Electrode, and details the studies conducted to demonstrate its substantial equivalence to a legally marketed predicate device (ERG Jet Electrode). However, it does not contain information about an AI/algorithm-based device analysis or a multi-reader multi-case (MRMC) study. The acceptance criteria and performance data presented relate to the physical and electrical characteristics of the electrode itself, as well as its performance in recording electroretinography (ERG) signals, rather than the performance of an AI algorithm based on image analysis.
Therefore, the following information cannot be extracted from the provided text:
- Acceptance Criteria for AI/Algorithm Performance: The document does not specify acceptance criteria for an AI algorithm's performance (e.g., sensitivity, specificity, AUC).
- Reported Device Performance (for AI): No performance metrics for an AI algorithm are reported.
- Sample Size for Test Set (for AI): No test set sample size for an AI study is mentioned.
- Data Provenance (for AI): No information on origin or nature of data for AI.
- Number of Experts and Qualifications (for AI Ground Truth): Not applicable as there's no AI ground truth discussed.
- Adjudication Method (for AI Ground Truth): Not applicable.
- Multi Reader Multi Case (MRMC) Comparative Effectiveness Study: The document does not mention an MRMC study.
- Standalone (algorithm only) Performance: No standalone AI performance is described.
- Type of Ground Truth (for AI): Not applicable.
- Sample Size for Training Set (for AI): No training set sample size for AI.
- How Ground Truth for Training Set was Established (for AI): Not applicable.
Instead, the document focuses on the performance of the physical electrode. Here's a summary of the acceptance criteria and studies that are present in the text, relating to the RM Electrode as a medical device:
1. Table of Acceptance Criteria and Reported Device Performance (Physical Electrode)
| Acceptance Criteria Category | Specific Acceptance Criteria (Implied/Direct) | Reported Device Performance |
|---|---|---|
| Biocompatibility | No cytotoxicity, sensitization, or ocular irritation (in animals or humans). Ocular irritation (bulbar redness, limbal redness, tarsal redness, corneal abrasion) to be equivalent to or less than predicate during extended wear. | Successfully completed testing for cytotoxicity, sensitization, and ocular irritation. |
| Lead Wire Integrity | Lead wire-electrode ring junction withstands a minimum failure load. | Subject device failure load was significantly higher (better) than predicate. All samples met prospectively defined acceptance criteria for minimum failure load. |
| Electrical Impedance | Electrical impedance at three frequencies within ERG signal passband to be equivalent to or less than predicate. | At all frequencies, the electrical impedance of the subject device was equivalent to, or less than (better) that of the predicate device. |
| Shelf Life | Maintenance of material hardness of eye contact portion; maintenance of electrical impedance at three frequencies within ERG signal passband; package integrity (seal strength, bubble leak) after accelerated aging. | Device properties (material hardness and electrical impedance) confirmed before and after accelerated aging. All samples met acceptance criteria demonstrating no significant changes. Integrity of sterile packaging confirmed through seal strength and bubble leak testing before and after accelerated aging. |
| Clinical Performance | Substantially equivalent (comparable) ERG signal quality (amplitudes, signal-to-noise ratios) to predicate device in full-field flash and 30 Hz flicker ERG protocols. No adverse events or complications. | Amplitudes (a-wave, b-wave, and flicker) and signal to noise ratios were substantially equivalent for both devices. No adverse events or complications related to the subject device reported in clinical performance study or ocular irritation study. |
2. Sample Sizes Used for the Test Set and Data Provenance:
- Clinical Performance Study: 15 subjects (sequentially wore both devices in the same eye).
- Human Ocular Irritation Study: 10 subjects.
- Data Provenance: Not explicitly stated (e.g., country of origin). Both clinical studies appear to be prospective studies conducted specifically for this submission.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of those Experts:
- Not applicable in the context of "ground truth" for an AI algorithm.
- For the clinical studies, results were likely evaluated by ophthalmologists or trained medical professionals conducting the ERG procedures, but the specific number or qualifications of these "experts" used for data analysis/interpretation (beyond general "Ophthalmologists, optometrists, trained medical technicians and professionals and vision science researchers" listed as intended users) establishing a definitive "ground truth" for comparative effectiveness are not detailed. The comparison was based on quantitative ERG signal parameters.
4. Adjudication Method for the Test Set:
- Not applicable in the context of AI ground truth adjudication.
- For the clinical studies, comparison was based on quantitative measurements (amplitudes, signal-to-noise ratios, and objective measures of irritation). There's no mention of a reading or adjudication process beyond standard clinical data collection.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No, an MRMC comparative effectiveness study was not done. The device is a physical electrode, not an AI diagnostic tool that assists human readers.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- No, this is not an algorithm-only device. It is a physical medical electrode.
7. The Type of Ground Truth Used:
- For the clinical performance and ocular irritation studies, the "ground truth" was established by quantitative measurements of ERG signals (amplitudes, signal-to-noise ratios) and objective clinical observations of ocular irritation (bulbar redness, limbal redness, tarsal redness, corneal abrasion). This is based on direct physiological measurements and clinical assessment, not expert consensus on an interpretation task like in AI.
8. The Sample Size for the Training Set:
- Not applicable. This device does not use a training set as it is not an AI/machine learning product.
9. How the Ground Truth for the Training Set was Established:
- Not applicable.
{0}------------------------------------------------
December 7, 2023
Image /page/0/Picture/1 description: The image shows the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text. The logos are displayed side-by-side.
RetMap, Inc. Shresta Patangay Chief of Staff 832 W Superior St, Suite 202 Chicago, Illinois 60642
Re: K232273
Trade/Device Name: RM Electrode (RMH 23-01) Regulation Number: 21 CFR 886.1220 Regulation Name: Corneal electrode Regulatory Class: Class II Product Code: HLZ Dated: November 3, 2023 Received: November 3, 2023
Dear Shresta Patangay:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
{1}------------------------------------------------
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerelv.
Elvin Y.
Elvin Ng Assistant Director DHT1A: Division of Ophthalmic Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
{2}------------------------------------------------
Indications for Use
Submission Number (if known)
Device Name
RM Electrode (RMH 23-01)
Indications for Use (Describe)
The RM Electrode® is a contact lens electrode intended to be applied on the cornea and to be used for the measurement and recording of electroretinography (ERG) signals, to support the diagnosis of retinal dysfunctions. It is indicated for use in patients aged 12 years and above undergoing diagnostic full-field electroretinogram (ERG) recording procedures.
The RM Electrode® is a single use, disposable device.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) Summary
K232273
| Submitter's Name | RetMap, Inc.832 W Superior St., Suite 202Chicago, IL 60642Telephone: (312) 224-8938 |
|---|---|
| Contact Person | Shresta Patangay, PhDChief of StaffRetMap, Inc.832 W Superior St., Suite 202Chicago, IL 60642 |
| Date Prepared | July 28, 2023 |
| Device Trade Name | RM Electrode |
| Device Common Name | Corneal or ERG Electrode |
| Classification Name | Corneal Electrode |
| Product Code | HLZ |
| Device Classification | Class II |
| Panel | Ophthalmology |
| Regulatory Classification | 21 CFR 886.1220 |
| Type of 510(k) Submission | Traditional |
| Legally Marketed Predicate Device | ERG Jet Electrode (K813399) |
Premarket Notification (510(k)) Number
{4}------------------------------------------------
Description
The RM Electrode® is a contact lens-type corneal electrode for use in electroretinography (ERG) procedures. Like other corneal electrodes classified under 21 CFR 886.1220 and cleared under product code HLZ, the RM Electrode is used for the measurement and recording of ERG signals, to support the diagnosis of retinal dysfunctions. It has four components, including (1) the contact lens (substrate), which supports the conductive element (electrode ring) and allows light from the stimulus source to enter the eye; (2) the electrode ring, which is the conductive element of the device; (3) the lead wire, which is connected to the electrode ring extension and terminates in an industry standard 1.5mm female "touchproof" connector that connects to a commercially available ERG recording system (not part of the subject device); and (4) heat shrink tubing which covers the electrode ring extension and junction with the lead wire. The device materials were demonstrated to be biocompatible.
The RM Electrode® is not a powered device. As with the predicate device (ERG Jet Electrode), it is a passive sensor for recording bioelectric signals from the surface of the eye and transmitting them to an ERG recording system. From an electrical perspective, the device is a single conductor that connects the eye surface to a data recorder.
Indications for Use
The RM Electrode® is a contact lens electrode intended to be applied on the cornea and to be used for the measurement and recording of electroretinography (ERG) signals, to support the diagnosis of retinal dysfunctions. It is indicated for use in patients aged 12 years and above undergoing diagnostic full-field electroretinogram (ERG) recording procedures.
The RM Electrode® is a single use, disposable device.
Predicate Device
The RM Electrode® is substantially equivalent to the ERG Jet Electrode cleared under K813399. Both devices are electrodes intended to be applied on the cornea for the measurement and recording of ERG signals, to support the diagnosis of retinal dysfunctions. Both the subject and predicate devices have the same intended use and similar technological characteristics, but the RM Electrode includes a softer eye contact material and design features that help prevent the wearer from blinking during the ERG test, improve positional stability, and keep the area of the pupil clear of obstructions.
{5}------------------------------------------------
Please refer to the Substantial Equivalence Summary Comparison Table below for a summary of the similarities and differences between the subject and predicate devices.
Description of Operation
As part of an ERG procedure, the device is filled with a lubricating ophthalmic solution and placed on the eye. The lead wire is gently draped over the ipsilateral ear, secured with tape if needed, and the connector is plugged into a compatible ERG recording system. The device can be used for any full-field ERG protocol to record bioelectric signals from the surface of the eye and transmit them to the ERG data recording system. After the ERG test procedure, the device is removed from the patient's eye.
Technological Characteristics Summary
The RM Electrode is substantially equivalent to the ERG Jet Electrode (K813399) with respect to intended use, design, principle of operation, technological characteristics and performance. Both devices include similar components, including a contact lens (eye contact) portion, electrode, and lead wire with connector. The RM Electrode includes a softer eye contact material and design features that help prevent the wearer from blinking during the ERG test, improve positional stability, and keep the area of the pupil clear of obstructions. These differences do not raise new questions of safety or effectiveness.
| Features | RM Electrode(Subject Device) | ERG Jet ElectrodePredicate DeviceK813399 | Comparison |
|---|---|---|---|
| Intended Use | Corneal (contact lens) electrode to transmit the retinal electrical signal in diagnostic ERG procedures | Corneal (contact lens) electrode to transmit the retinal electrical signal in diagnostic ERG procedures | Identical |
| Product Code | HLZ | HLZ | Identical |
| Indications for Use | The RM Electrode® is a contact lens electrode intended to be applied on the cornea and to be used for the measurement and recording of | The ERG-Jet is a contact lens electrode intended to be applied on the cornea and to be used for the measurement and recording of | Equivalent. While the predicate device is intended for use in both full-field flash and multi-focal ERG procedures, the subject device is |
| electroretinography(ERG) signals, tosupport the diagnosis ofretinal dysfunctions. Itis indicated for use inpatients aged 12 yearsand above undergoingdiagnostic full-fieldelectroretinogram(ERG) recordingprocedures.The RM Electrode® is asingle use, disposabledevice. | electroretinography(ERG) signals, tosupport the diagnosis ofretinal dysfunctions.The ERG-Jet is notintended for multipleuse. If re-used, aninfection of the corneacan occur, and themeasuring results are nolonger guaranteed. | currently intendedonly for use in full-field flash ERGprocedures. Full-field flash protocolsrepresent themajority(approximately80%) of the ERGproceduresconducted in theUnited States,therefore thisdifference is notcritical to theintended use of thedevice and does notaffect the safety oreffectiveness of thedevice when used aslabeled. The devicelabeling clearlyidentifies theintended use for full-field flashprocedures only. | |
| Target Population | Patients aged 12 yearsand above undergoingERG recordingprocedures | Patient population notspecified | Both devices are usedin patients undergoingERG procedures |
| Types of ERGProcedures | Full-field flash ERGprotocols | Either full-field ormultifocal ERG protocols | The RM Electrode isnot intended for ERGprotocols that usepatterned visualstimuli, such as themulti-focal ERG(mfERG). Full-fieldflash protocolsrepresentapproximately 80% ofERG procedures that |
| are conducted in the | |||
| US thus this | |||
| difference is not | |||
| critical to the intended | |||
| use of the device and | |||
| does not affect the | |||
| safety or effectiveness | |||
| of the device when | |||
| used as labeled. | |||
| Wear Duration | Typically 20 minutes.< 1 hour | Typically 20 minutes.< 1 hour | Identical |
| Intended Users | Ophthalmologists,optometrists, trainedmedical technicians andprofessionals and visionscience researchers | Ophthalmologists andoptometrists practicing inophthalmic hospitals,clinics and medicalsettings | Equivalent intendedusers |
| Environment ofUse | Hospitals, clinics,physician offices,research labs | Ophthalmic hospitals,clinics and medicalsettings | Equivalent medicalsetting useenvironments |
| Components | Contact lens, electrodering, lead wire with1.5mm touchproofconnector that connects toERG data recorder | Contact lens, electrode,lead wire with 1.5mmtouchproof connector thatconnects to ERG datarecorder | Equivalentcomponents |
| Materials | Biocompatible materials | Biocompatible materials | Equivalent materials |
| Compatible ERGRecorders | ERG recording systemaccepting 1.5mmtouchproof connectorthat complies with allapplicable device safetystandards, such as IEC60601-1 | ERG recording systemaccepting 1.5mmtouchproof connectorthat complies with allapplicable device safetystandards, such as IEC60601-1 | Identical |
Substantial Equivalence Summary Comparison Table
{6}------------------------------------------------
{7}------------------------------------------------
Performance Testing
As described below, a comprehensive battery of biocompatibility, bench, and clinical studies was submitted to confirm product conformance with device requirements. Performance data demonstrated biocompatibility, absence of ocular irritation in both animals and humans, and substantially equivalent performance to the predicate device in terms of ERG signal quality, lead
{8}------------------------------------------------
wire integrity and electrical impedance. The biocompatibility, bench, shelf life, and clinical studies summarized below concluded that the device is as safe, as effective, and performs as well or better than the legally marketed predicate device.
Biocompatibility Testing
Biocompatibility testing was conducted in accordance with ISO 10993. Testing was successfully completed for cytotoxicity, sensitization and ocular irritation. In addition, human ocular irritation was completed following 60 minutes of wear time (approximately 3 times the typical 20-minute wear duration) in 10 subjects with both the subject and predicate devices. Bulbar redness, limbal redness, tarsal redness, and corneal abrasion associated with wear of the subject device were found to be equivalent to, or less than, that associated with wear of the predicate device.
Bench Testing
The subject and predicate device were tested under tensile load to determine the failure load for the lead wire-electrode ring junction. The subject device failure load was significantly higher (better) than that for the predicate device. In addition, all samples of the subject device met the prospectively defined acceptance criteria for the minimum failure load.
The subject and predicate device were also evaluated for electrical impedance measured at three frequencies within the passband of the ERG signal. At all frequencies, the electrical impedance of the subject device was equivalent to, or less than (better) that of the predicate device.
Shelf Life Testing
The device and its packaging successfully completed evaluations after accelerated aging to support the labeled shelf life. Integrity of the sterile packaging was confirmed before and after accelerated aging through seal strength and bubble leak testing. Device properties were confirmed before and after accelerated aging through evaluation of material hardness of the eye contact portion of the device using a calibrated durometer and through evaluation of the electrical impedance of the device measured at three frequencies within the passband of the ERG signal. All samples met the acceptance criteria demonstrating no significant changes over the labeled shelf life.
Clinical Testing
Clinical performance testing was compared using the subject and predicate devices in 15 subjects at two sites who sequentially wore both devices in the same eye in a randomized order. Subjects
{9}------------------------------------------------
were healthy with no history of retinal disease or corneal surgery. Full-field flash (ISCEV LA 3.0 stimulus) and 30 Hz flicker ERG protocols were followed. Amplitudes (a-wave, b-wave and flicker) and signal to noise ratios were substantially equivalent for both devices. There were no adverse events or complications related to the subject device.
In addition, as noted in the Biocompatibility section above, human ocular irritation was completed following 60 minutes of wear time (approximately 3 times the typical wear duration) in 10 subjects with both the subject and predicate devices. Subjects were normally sighted aged 18 years and above. Bulbar redness, limbal redness, tarsal redness, and corneal abrasion associated with wear of the subject device were found to be equivalent to, or less than, that associated with wear of the predicate device. There were no adverse events or complications related to the study device.
Conclusions
The nonclinical and clinical studies demonstrated the subject device is (1) biocompatible (lack of cytotoxicity, ocular irritation in animals or humans, or sensitization); (2) maintains device (material hardness of the eye contact portion and electrical impedance) and package integrity (seal strength and bubble leak) after a 1-year shelf life; (3) has substantially equivalent or better performance with respect to lead wire integrity and electrical impedance compared to the predicate device; and (4) can be used successfully in full-field ERG protocols with comparable results (amplitudes and signal to noise ratios) as the predicate device. These results demonstrate that the RM Electrode is as safe, as effective, and performs as well or better than the legally marketed device identified above.
Summary
In summary, the RM Electrode is substantially equivalent to the predicate ERG Jet Electrode with respect to intended use, technological characteristics and performance. The biocompatibility, bench, shelf life, and clinical studies concluded that the device is as safe, as effective, and performs as well or better than the legally marketed predicate device.
§ 886.1220 Corneal electrode.
(a)
Identification. A corneal electrode is an AC-powered device, usually part of a special contact lens, intended to be applied directly to the cornea to provide data showing the changes in electrical potential in the retina after electroretinography (stimulation by light).(b)
Classification. Class II.